$91.64
0.40% yesterday
Nasdaq, May 01, 09:48 pm CET
ISIN
US89377M1099
Symbol
TMDX

TransMedics Group, Inc. Stock price

$90.45
+22.18 32.49% 1M
+8.05 9.77% 6M
+28.10 45.07% YTD
-27.15 23.09% 1Y
+68.45 311.14% 3Y
+73.86 445.21% 5Y
+74.45 465.31% 10Y
Nasdaq, Closing price Thu, May 01 2025
-1.56 1.70%
ISIN
US89377M1099
Symbol
TMDX
Sector

Key metrics

Market capitalization $3.06b
Enterprise Value $3.24b
P/E (TTM) P/E ratio 89.54
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.34
P/S ratio (TTM) P/S ratio 6.93
P/B ratio (TTM) P/B ratio 13.30
Revenue growth (TTM) Revenue growth 82.74%
Revenue (TTM) Revenue $441.54m
EBIT (operating result TTM) EBIT $37.50m
Free Cash Flow (TTM) Free Cash Flow $-80.94m
Cash position $336.65m
EPS (TTM) EPS $1.01
P/E forward 64.94
P/S forward 5.64
EV/Sales forward 5.97
Short interest 44.86%
Show more

Is TransMedics Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,792 stocks worldwide.

TransMedics Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

Buy
70%
Hold
30%

Financial data from TransMedics Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
442 442
83% 83%
100%
- Direct Costs 180 180
105% 105%
41%
262 262
70% 70%
59%
- Selling and Administrative Expenses 148 148
34% 34%
34%
- Research and Development Expense 56 56
55% 55%
13%
57 57
698% 698%
13%
- Depreciation and Amortization 20 20
128% 128%
4%
EBIT (Operating Income) EBIT 37 37
2,575% 2,575%
8%
Net Profit 35 35
242% 242%
8%

In millions USD.

Don't miss a Thing! We will send you all news about TransMedics Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransMedics Group, Inc. Stock News

Neutral
PRNewsWire
8 days ago
ANDOVER, Mass. , April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025.
Negative
The Motley Fool
8 days ago
President Donald Trump's trade war is creating significant uncertainty. Equities plunged following his decision to impose tariffs on almost every country, then soared after he announced a 90-day pause on his expanded tariff plans.
Negative
Seeking Alpha
9 days ago
TransMedics recently fell over 50% due to missing analyst's expectations on revenue and EPS. Zooming out, they still grew at incredible rates and are likely to continue to do so. Key risks are a very small TAM and some financial levels deteriorating.
More TransMedics Group, Inc. News

Company Profile

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

Head office United States
CEO Waleed Hassanein
Employees 728
Founded 1998
Website www.transmedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today